Antibodies have become a cornerstone of modern research and in vitro diagnostics, generating yearly revenues close to 2 billion dollars. Most of these are produced in mice, despite some significant intrinsic limitations of mouse antibodies. Belgian spin-off company SynAbs now presents a highly interesting alternative: rat antibodies. By shifting from mouse antibodies to rat antibodies, many new advantages can be exploited to make antibody technology even better.
SynAbs proposes a catalog of more than 100 rat and mice monoclonal antibodies.
SynAbs maximizes the success rate and the quality of the mAbs generated in rats and mice. >> more about our technology
SynAbs is a dedicated Monoclonal Antibody Manufacturing Center.
>> read more about our team
Boston, USA, PEGS
Ghent, BE, Value for Growth, Booth 88
Aachen, DE, Biomedica